New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?

David Spigel, MD

Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes.

Related Videos

July 13, 2021

Making a Difference with Early Identification and Treatment of Patients with NTRK Gene Fusions

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain the benefits of testing for TRK fusion–positive tumors early for improved clinical outcomes.

March 31, 2015

Combining Novel Agents for CLL

Dr. Jennifer R. Brown talks about combining novel agents for treating CLL as the next step to achieve longer remissions for patients. Until now, novel agents have only been used individually or in combination with antibodies. New studies are being designed to measure the efficacy of combining novel agents with [ Read More ]